Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Refractory Cold Agglutinin Disease
NCT01696474Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Dec 2012
- Primary completion
- Mar 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in cold agglutinin disease (CAD), sponsored by GIMEMA. Started Dec 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT01696474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696474.